晚期低级别浆液性卵巢癌中残留病灶与手术时机对生存的影响:系统综述与荟萃分析
该系统综述与荟萃分析纳入19项回顾性队列研究共3361例FIGO III-IV期低级别浆液性卵巢癌患者,评估初次肿瘤细胞减灭术(PCS)后残留病灶(RD)的预后影响并比较PCS与新辅助化疗后间歇性减瘤术(NAC-IDS)的生存结局。PCS后肉眼残留病灶(CC2)与更差的无进展生存期(PFS)和总生存期(OS)显著相关,PCS较NAC-IDS与更优的PFS和OS相关。作者认为CC0/CC1是晚期LGSOC的关键预后因素,在可行时应优先选择PCS而非新辅助策略。
要点
- PCS后肉眼残留病灶(CC2)与更差PFS(HR=2.71,95%CI:2.27-3.23)和OS(HR=3.06,95%CI:2.44-3.82)显著相关。
- PCS较NAC-IDS与更优PFS(HR=1.72,95%CI:1.19-2.48)和OS(HR=2.06,95%CI:1.47-2.89)相关。
- 作者认为CC0/CC1是晚期LGSOC的关键预后因素,可行时应优先选择PCS。
核心结论
- 完全或近完全肿瘤细胞减灭(CC0/CC1)是晚期低级别浆液性卵巢癌的关键预后因素。
- 在可行时,应优先选择初次肿瘤细胞减灭术而非新辅助策略,以改善这一化疗耐药卵巢癌亚型的生存结局。
研究设计与样本
- 系统检索PubMed和Scopus数据库,纳入2005年1月至2024年1月发表的回顾性队列研究。
- 纳入报告FIGO III-IV期低级别浆液性卵巢癌患者PFS和/或OS、按残留病灶范围或手术时机(PCS vs NAC-IDS)分层的研究。
- 排除病例报告、综述和非英文研究;两位评价者独立筛选文献并提取数据。
- 采用随机效应荟萃分析模型合并PFS和OS的风险比(HR),残留病灶按CC评分分为CC0/CC1(无或微小残留)与CC2(肉眼残留)。
- 共纳入19项研究3361例患者,89.1%的患者接受了PCS。
主要发现
- PCS后肉眼残留病灶(CC2)较CC0/CC1与显著更差的PFS相关(HR=2.71,95%CI:2.27-3.23)。
- PCS后肉眼残留病灶(CC2)较CC0/CC1与显著更差的OS相关(HR=3.06,95%CI:2.44-3.82)。
- PCS较NAC-IDS与更优的PFS相关(HR=1.72,95%CI:1.19-2.48)。
- PCS较NAC-IDS与更优的OS相关(HR=2.06,95%CI:1.47-2.89)。
- 研究间异质性为中至高度,但方向一致。
关键数值与推荐
- 残留病灶按CC评分分类:CC0/CC1(无或微小残留病灶)对比CC2(肉眼残留病灶)。
- PCS后CC2较CC0/CC1的PFS HR=2.71(95%CI:2.27-3.23)。
- PCS后CC2较CC0/CC1的OS HR=3.06(95%CI:2.44-3.82)。
- PCS较NAC-IDS的PFS HR=1.72(95%CI:1.19-2.48)。
- PCS较NAC-IDS的OS HR=2.06(95%CI:1.47-2.89)。
临床怎么用
- 作者认为完全或近完全肿瘤细胞减灭(CC0/CC1)是晚期低级别浆液性卵巢癌的关键预后因素。
- 作者认为在可行时应优先选择初次肿瘤细胞减灭术而非新辅助策略,以改善生存结局。
局限性
- 研究间异质性为中至高度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: To assess the prognostic impact of residual disease (RD) after primary cytoreductive surgery (PCS) and to compare survival outcomes between PCS and neoadjuvant chemotherapy followed by interval debulking surgery (NAC-IDS) in patients with advanced-stage low-grade serous ovarian cancer (LGSOC). METHODS: A systematic search of PubMed and Scopus databases was conducted to identify relevant studies published from January 2005 to January 2024. We included retrospective cohort studies reporting progression-free survival (PFS) and/or overall survival (OS) in patients with FIGO stage III-IV LGSOC, stratified by the extent of residual disease after cytoreductive surgery and/or the timing of surgery (PCS vs NAC-IDS). Case reports, reviews, and non-English studies were excluded. Two reviewers independently screened articles and extracted data. Hazard ratios (HRs) for PFS and OS were pooled using a random-effects meta-analysis model. Residual disease was categorized using the Completeness of Cytoreduction (CC) score: CC0/CC1 (no or minimal RD) versus CC2 (macroscopic RD). Statistical heterogeneity was assessed using the I2 statistic. RESULTS: Nineteen studies encompassing 3361 patients were included. PCS was performed in 89.1 % of patients. The presence of macroscopic RD (CC2) after PCS was associated with significantly poorer PFS (HR = 2.71, 95 % CI: 2.27-3.23) and OS (HR = 3.06, 95 % CI: 2.44-3.82) compared to CC0/CC1. PCS was associated with superior PFS (HR = 1.72, 95 % CI: 1.19-2.48) and OS (HR = 2.06, 95 % CI: 1.47-2.89) compared to NACT-IDS. Heterogeneity across studies was moderate to high but consistent in direction. CONCLUSIONS: Complete or near complete cytoreduction (CC0/CC1) is a key prognostic factor in advanced LGSOC. Whenever feasible, PCS should be prioritized over neoadjuvant strategies to improve survival outcomes in this chemoresistant ovarian cancer subtype. PROSPERO REGISTRATION: Registration number: CRD420250621053. https://www.crd.york.ac.uk/PROSPERO/view/CRD420250621053.
引用
- Hotton J, Gaillard T, Paoletti X, et al. Survival impact of residual disease and timing of surgery in the management of advanced-stage low grade serous ovarian cancer: A systematic review and meta-analysis. Gynecol Oncol. 2025. PMID: 41129877. doi:10.1016/j.ygyno.2025.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。